risperidone has been researched along with Hypogonadism in 5 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Hypogonadism: Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Risperidone is a novel antipsychotic agent that blocks both dopaminergic and serotonergic receptors." | 5.31 | Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. ( Tollin, SR, 2000) |
| " The objective of this study was to determine the prevalence of low BMD in patients with schizophrenia treated with conventional antipsychotics or risperidone and to evaluate any potential relationship with treatment." | 5.17 | Bone loss associated with hyperprolactinemia in patients with schizophrenia. ( Jacob, J; Kinon, BJ; Liu-Seifert, H; Stauffer, VL, 2013) |
| "Hypogonadotropic hypogonadism is a rare congenital disorder characterised by the deficiency and the absence of puberty and infertility." | 1.48 | Rare cause of manic period trigger in bipolar mood disorder: testosterone replacement. ( Elboga, G; Sayiner, ZA, 2018) |
| "Risperidone is a novel antipsychotic agent that blocks both dopaminergic and serotonergic receptors." | 1.31 | Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. ( Tollin, SR, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elboga, G | 1 |
| Sayiner, ZA | 1 |
| Kinon, BJ | 1 |
| Liu-Seifert, H | 1 |
| Stauffer, VL | 1 |
| Jacob, J | 1 |
| Valiquette, G | 1 |
| Meaney, AM | 1 |
| O'Keane, V | 1 |
| Tollin, SR | 1 |
1 trial available for risperidone and Hypogonadism
| Article | Year |
|---|---|
Bone loss associated with hyperprolactinemia in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Bone Density; Bone Resorption; Cross-Sectional Studies; Estradiol; Fema | 2013 |
4 other studies available for risperidone and Hypogonadism
| Article | Year |
|---|---|
Rare cause of manic period trigger in bipolar mood disorder: testosterone replacement.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Chorionic Gonadotropin; Hormone Rep | 2018 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Adult; Antipsychotic Agents; Autistic Disorder; Humans; Hyperprolactinemia; Hypogonadism | 2002 |
Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication.
Topics: Adult; Antipsychotic Agents; Bone Density; Female; Humans; Hyperprolactinemia; Hypogonadism; Male; O | 2003 |
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
Topics: Adult; Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Human | 2000 |